Researchers found that a protein called Dusp15 plays an important role in protecting the heart from damage caused by diabetes. When they studied mice with diabetes, they discovered that hearts with more Dusp15 worked better and showed less damage. The protein appears to work by helping another protein called mtHsp70 fix problems inside the heart’s energy-producing structures called mitochondria. This discovery suggests that boosting Dusp15 levels could become a new way to treat heart problems in people with diabetes.
The Quick Take
- What they studied: Whether a protein called Dusp15 can protect heart function in diabetes and how it works to prevent heart damage
- Who participated: Laboratory mice with diabetes (created by special diet and injections), heart cells grown in dishes, and genetically modified mice designed to study specific proteins
- Key finding: Mice with more Dusp15 protein had better heart function and less heart damage from diabetes, while mice without Dusp15 had worse outcomes. The protein works by activating a repair system inside the heart’s mitochondria (the cell’s power plants)
- What it means for you: This research suggests that future treatments targeting Dusp15 might help protect hearts in people with diabetes, but this is early-stage research and human studies are needed before any new treatments could be available
The Research Details
Scientists created several groups of laboratory mice to study how Dusp15 affects diabetic heart disease. One group had diabetes induced through a special high-fat diet combined with a chemical injection. Other mice were genetically modified to either have extra Dusp15 or have it removed specifically in heart cells. The researchers also grew heart cells in dishes and exposed them to high glucose levels to mimic diabetes. They measured heart function using ultrasound imaging (echocardiography) and examined heart tissue under microscopes to see structural changes.
The team investigated how Dusp15 works by studying its interactions with another protein called mtHsp70. They used genetic models where they changed a specific spot on mtHsp70 to understand its role in the protective process. They also tested a diabetes medication called dapagliflozin to see if Dusp15 was involved in how it helps the heart.
This multi-pronged approach allowed researchers to establish that Dusp15 is necessary for heart protection and to identify the specific mechanism through which it works.
This research approach is important because it moves beyond simply observing that a protein is involved in disease—it actually proves that the protein is necessary for protection and identifies the exact pathway it uses. By testing both gain-of-function (adding more) and loss-of-function (removing) versions, the researchers could confirm Dusp15’s role. The genetic models of mtHsp70 helped pinpoint exactly how the protection works at the molecular level.
This is a well-designed laboratory study published in a peer-reviewed journal focused on cardiovascular disease and diabetes. The researchers used multiple complementary approaches (animal models, cell cultures, and genetic modifications) to confirm their findings, which strengthens confidence in the results. However, this is fundamental research in mice and cells—it has not yet been tested in humans. The specific sample sizes for each experiment are not provided in the abstract, which is a limitation for assessing statistical power.
What the Results Show
The main discovery was that Dusp15 levels are reduced in hearts affected by diabetes. When researchers increased Dusp15 in diabetic mice, their hearts functioned better and showed less remodeling (structural changes) and inflammation compared to diabetic mice with normal Dusp15 levels. Conversely, when they removed Dusp15 from heart cells in diabetic mice, the heart damage was significantly worse.
The researchers found that Dusp15 works by interacting with and supporting a protein called mtHsp70, which is responsible for fixing damaged proteins inside mitochondria (the cell’s power plants). This repair system, called the mito-UPR (mitochondrial unfolded protein response), is crucial for maintaining healthy mitochondria under stress.
In genetic experiments, mice that had a modified version of mtHsp70 (mtHsp70T116A) were substantially protected from diabetic heart dysfunction and remodeling, suggesting this specific interaction is key to the protective effect. This finding helps explain the mechanism by which Dusp15 provides protection.
When the researchers tested dapagliflozin, a medication already used to treat diabetes and heart problems, they found that its benefits were reduced in mice lacking Dusp15, suggesting that Dusp15 is an important part of how this medication helps protect the heart.
The study showed that Dusp15 reduces inflammation in the diabetic heart, which is important because inflammation contributes to heart damage. The protein also appears to preserve the normal function of mitochondria, which are essential for providing energy to heart cells. These secondary findings support the idea that Dusp15 works through multiple protective pathways, not just one mechanism.
This research builds on previous knowledge that mitochondrial stress and protein damage are major problems in diabetic heart disease. However, the specific role of Dusp15 in this process was previously unknown. The findings fit with existing research showing that proteins that regulate phosphorylation (a chemical modification) are important for controlling cellular stress responses. This study adds to growing evidence that the mito-UPR pathway is a promising target for treating diabetic heart disease.
This research was conducted entirely in laboratory mice and cultured cells, not in humans. Mouse studies don’t always translate directly to human biology. The abstract doesn’t provide specific sample sizes for each experiment, making it difficult to assess statistical power. The study doesn’t include long-term follow-up data on whether the protective effects persist over time. Additionally, while the research identifies Dusp15 as important, it doesn’t yet show whether increasing Dusp15 levels would be safe and effective as a treatment in humans.
The Bottom Line
Based on this research alone, there are no direct recommendations for patients. This is fundamental research that identifies a potential therapeutic target. People with diabetes should continue following their doctor’s advice regarding blood sugar control, exercise, diet, and prescribed medications. Future human clinical trials would be needed before any Dusp15-based treatment could be recommended. Current diabetes medications like dapagliflozin remain the evidence-based standard of care.
This research is most relevant to people with diabetes who have or are at risk for heart problems, as well as researchers and pharmaceutical companies developing new treatments. It may also interest cardiologists and endocrinologists who treat diabetic patients. However, this is early-stage research, so it’s not yet applicable to patient care decisions. People without diabetes don’t need to take action based on this finding.
This is fundamental research, so there is no immediate timeline for clinical application. Typically, it takes 10-15 years or more for discoveries in laboratory research to become available treatments for patients. The next steps would involve testing Dusp15-targeting approaches in larger animal studies, then eventually in human clinical trials if those results are promising.
Want to Apply This Research?
- Users with diabetes could track their heart health markers including resting heart rate, blood pressure readings, and any symptoms of heart stress (shortness of breath, unusual fatigue, chest discomfort). While this research doesn’t yet suggest a specific intervention to track, monitoring these baseline metrics would be valuable if Dusp15-targeting treatments become available in the future.
- Although this research doesn’t yet suggest specific behavioral changes, users with diabetes should maintain or improve current heart-healthy habits: regular moderate exercise (150 minutes per week), heart-healthy diet (Mediterranean or DASH diet), stress management, adequate sleep, and medication adherence. These evidence-based practices support mitochondrial health and may complement future Dusp15-based therapies.
- Users should work with their healthcare provider to monitor standard heart health indicators including blood pressure, heart rate variability, and symptoms. As research progresses and if Dusp15-targeting treatments become available, apps could be updated to track specific biomarkers related to mitochondrial stress and the mito-UPR pathway.
This research describes laboratory findings in mice and cultured cells and has not been tested in humans. It does not suggest any changes to current diabetes or heart disease treatment. People with diabetes should continue following their healthcare provider’s recommendations regarding blood sugar management, medications, diet, and exercise. Anyone concerned about heart health or diabetes complications should consult with their doctor. This article is for educational purposes only and should not be used to make medical decisions. Future human clinical trials would be necessary before any Dusp15-based treatment could be recommended for patient use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.